Safe Supply Announces Upsize to Non-Brokered Private Placement
Toronto, Ontario--(Newsfile Corp. - December 9, 2025) - Safe Supply Streaming Co Ltd. (CSE: SPLY) (OTCQB: SSPLF) (FSE: QM4) ("Safe Supply" or the "Company"), a pioneer in the health, safety and rapid response technologies, is pleased to announce that due to significant interest, it has upsized its proposed private placement of units ("Units") at a price of $0.05 per Unit to up to $1,000,000 in aggregate gross proceeds (the "Offering"). All other terms of the
2025-12-09 10:30 AM EST | Safe Supply Streaming Co Ltd.
Custom Health Announces First Closing of Brokered Private Placement of Subscription Receipts for Gross Proceeds of US$9.6M
Kelowna, British Columbia--(Newsfile Corp. - December 9, 2025) - Custom Health Inc. ("Custom Health" or the "Company"), a vertically integrated, tech-enabled care platform, is pleased to announce that Custom FundCo Inc. ("FundCo") has completed the first closing (the "First Closing") of its previously announced brokered private placement financing of subscription receipts (the "Offering") being conducted in connection with the Company's proposed busin
Technology, Pharmaceuticals, Health
2025-12-09 9:40 AM EST | Custom Health
Aleen Inc. Introduces Wellness AI: A Journey into Self-Discovery, Not Medical Diagnosis
Toronto, Ontario--(Newsfile Corp. - December 9, 2025) - Aleen Inc. (CSE: ALEN.U), a digital wellness company, invites users to explore the philosophy behind its Wellness AI platform. From early concept testing to personal insight features, Aleen Inc. continues creating tools that help individuals notice habits, reflect on daily experiences, and uncover individual patterns — without medical assessments. Wellness AI is about seeing yourself clearly, understanding your
2025-12-09 8:00 AM EST | Aleen Inc.
Promino Announces Secured Convertible Debenture Offering for Proceeds of up to $1 Million
Burlington, Ontario--(Newsfile Corp. - December 9, 2025) - Promino Nutritional Sciences Inc. (CSE: MUSL) (OTC: MUSLF) (FSE: 93X) ("Promino" or the "Company") announces it intends to complete a non-brokered private placement of secured convertible debentures (the "Convertible Debentures") of the Company for an aggregate principal amount of up to $1 million (the "Offering"). The Company may increase the size of the Offering by up to an additional $500,000 of Convertible Debentures for aggregat
Food / Beverages, Sports, Health
2025-12-09 7:00 AM EST | Promino Nutritional Sciences, Inc.
Rapid Dose Completes Extension to Promissory Notes
Burlington, Ontario--(Newsfile Corp. - December 8, 2025) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") announced today that it has extended the maturity date of its outstanding secured convertible notes (the "Notes") previously issued on its private placement financing (the "Financing") which closed in 2023. The Notes had a maturity date of November 30, 2025, and the Company extended the maturity date for one year, to November 30, 2
2025-12-08 7:19 PM EST | Rapid Dose Therapeutics Corp.
TempraMed Announces Strategic Agreement with Maccabi Healthcare Services, a Leading HMO with over 2.8 Million Patients
Vancouver, British Columbia--(Newsfile Corp. - December 8, 2025) - TempraMed Technologies Ltd. (CSE: VIVI) ("TempraMed" or the "Company"), a medical technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce a major commercial milestone as part of its broader global expansion strategy: its flagship products, the VIVI Cap and VIVI EPI, are now available through Maccabi Healthcare Services, Israel's second-largest health
Technology, Biotechnology, Pharmaceuticals, Health
2025-12-08 5:00 PM EST | TempraMed Technologies Ltd
Adia Nutrition Inc. Files SEC Form 10 as Strategic Step Toward Full Reporting Status
Winter Park, Florida--(Newsfile Corp. - December 8, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), announced today that, with the assistance of Adia's Chief Financial Officer, and following review by the Company's auditing accountant, its Form 10 registration statement was prepared and submitted by Adia's corporate accountant and legal counsel to the U.S. Securities and Exchange Commission (SEC).
Healthcare and Hospitals, Health
2025-12-08 9:00 AM EST | Adia Nutrition Inc.
Functional Brands Inc. to Participate at the Sidoti Year End Virtual Investor Conference
Lake Oswego, Oregon--(Newsfile Corp. - December 8, 2025) - Functional Brands Inc. (NASDAQ: MEHA), a leading innovator in wellness and performance products, today announced that Eric Gripentrog, Chief Executive Officer & Director and David R. Wells, Financial Counsel will participate in the Sidoti Year End Virtual Investor Conference, to be held December 10-11, 2025. Mr. Gripentrog and Mr. Wells will meet virtually with investors and present at approximately 3:15 p.m. Eastern Time o
Household / Consumer / Cosmetics, Health
2025-12-08 8:00 AM EST | Functional Brands Inc.
Cheelcare Has a Record Month of Sales and Celebrates Milestone of 2,000 Companions Sold
Markham, Ontario--(Newsfile Corp. - December 8, 2025) - Cheelcare (TSXV: CHER), a Canadian innovator in advanced mobility solutions, is proud to announce that the Company has reached a major commercial milestone with the sale of its 2,000th Companion, coinciding with a record month of production and sales. This reflects accelerating market adoption and growing demand for innovative mobility solutions. The Companion is Cheelcare's flagship power-assist device, purpose-built to augment ma
2025-12-08 7:00 AM EST | Cheelcare Inc.
Predictmedix AI Announces Closing of Final Tranche of Non-Brokered Private Placement
Toronto, Ontario--(Newsfile Corp. - December 5, 2025) - Predictmedix AI Inc. (CSE: PMED) (OTC Pink: PMEDF) (FSE: 3QP0) ("Predictmedix" or the "Company"), an emerging leader in AI-powered health and safety technology, is pleased to announce that it has successfully closed the final tranche of its non-brokered private placement (the "Offering"). In this final tranche, the Company issued 3,050,000 units ("Units") at a price of $0.05 per Unit, for gross proceeds of $152,500, bringing the to
2025-12-05 5:02 PM EST | QScreen AI Inc.
TempraMed Expands European Footprint with Distribution Partnership in Netherlands, Belgium, and Luxembourg
Vancouver, British Columbia--(Newsfile Corp. - December 5, 2025) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical technology innovator transforming how temperature-sensitive medications are stored and managed, a pioneer in temperature-controlled solutions for injectable medications, has entered into a distribution partnership with Salomo Executive, a leading healthcare logistics and consultancy company based in the Netherlands
Technology, Biotechnology, Pharmaceuticals, Health
2025-12-05 5:00 PM EST | TempraMed Technologies Ltd
Restart Life Sciences Announces Closing First Tranche of Financing
Vancouver, British Columbia--(Newsfile Corp. - December 5, 2025) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") announces that further to its news release dated November 12, 2025, the Company has closed the first tranche of its non-brokered private placement for total gross proceeds of CDN$500,000 (the "Placement"). Pursuant to the Placement, the Company has allotted and issued 5,000,000 units (the "Units") at a p
Technology, Biotechnology, Health
2025-12-05 5:00 PM EST | Restart Life Sciences Corp.
Correction to MyndTec Inc. Press Release Issued December 3, 2025 Regarding Non-Brokered Private Placement
Mississauga, Ontario--(Newsfile Corp. - December 5, 2025) - MyndTec Inc. (CSE: MYTC) ("MyndTec" or the "Company"), announced today a correction to its press release titled "MyndTec Inc. Completes Eighth Tranche of Non-Brokered Private Placement" issued on December 3, 2025 (the "Initial Press Release"). The Initial Press Release incorrectly stated the number of units issued under the eighth tranche of the private placement Offering as 351,475 Units, the aggregate
Technology, Healthcare and Hospitals, Health
2025-12-05 4:30 PM EST | MyndTec Inc.
Hemostemix Welcomes Shaune Harding, OStJ, RN as Director of Patient Care & Clinical Operations
Calgary, Alberta--(Newsfile Corp. - December 4, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), a leader in autologous stem cell therapeutics for ischemic diseases, is pleased to announce the appointment of Shaune Harding, OStJ, RN non-practicing, as Director of Patient Care & Clinical Operations. In this senior clinical role, Ms. Harding will oversee: On-boarding of all new patients entering Hemostemix treatment programs;
Biotechnology, Pharmaceuticals, Health
2025-12-04 9:10 AM EST | Hemostemix Inc.
Rejuvenate Muscle Health Wins Prestigious "Best Drink" Award at 2025 ECRM Vitamin, Weight Management & Sports Nutrition Session
Burlington, Ontario--(Newsfile Corp. - December 4, 2025) - Promino Nutritional Sciences Inc. (CSE: MUS
Food / Beverages, Sports, Health
2025-12-04 7:00 AM EST | Promino Nutritional Sciences, Inc.
PreveCeutical Announces Grant of Patent for Innovative Pain Therapy Technology
Vancouver, British Columbia--(Newsfile Corp. - December 4, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCID: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical") is pleased to announce that the Australian Patent Office has granted Australian Patent No. AU2020212659, titled "A Cyclic Peptide", which relates to the Company's pain therapy program. This patent represents a significant milestone in the development and protection of PreveCeutical's proprie
Biotechnology, Pharmaceuticals, Health
2025-12-04 7:00 AM EST | PreveCeutical Medical Inc.
Defence Therapeutics Announces Formation of Scientific Advisory Board to Guide Advancement of Accum-Enhanced Antibody Drug Conjugate Programs
Montreal, Quebec--(Newsfile Corp. - December 4, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a biotechnology company advancing a proprietary intracellular delivery platform that enables more potent, safer, and more effective antibody-based and radiotherapeutic treatments, is pleased to announce the formation of its inaugural Scientific Advisory Board ("SAB"), composed of Rob Leanna, Danny Chui, and Brendan Hussey. Defence
Biotechnology, Pharmaceuticals, Health
2025-12-04 3:15 AM EST | Defence Therapeutics Inc.
MyndTec Inc. Completes Eighth Tranche of Non-Brokered Private Placement
Mississauga, Ontario--(Newsfile Corp. - December 3, 2025) - MyndTec Inc. (CSE: MYTC) ("MyndTec" or the "Company"), a neurological treatment and rehabilitation medical technology company, is pleased to announce that it has closed the eighth tranche of its non-brokered private placement previously announced on January 30, 2025 (the "Offering"). The eighth tranche of the private placement consists of 351,475 Units of the Company (the "Units") at a price of $0.20
Technology, Healthcare and Hospitals, Health
2025-12-03 5:00 PM EST | MyndTec Inc.
Hemostemix Featured at Innovations in Wound Healing 2025, Key West, December 11-14
Calgary, Alberta--(Newsfile Corp. - December 3, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce its participation as a premier regenerative medicine company at Innovations in Wound Healing 2025 in Key West, Florida, December 11-14, where global leaders in vascular surgery, wound care, diabetic limb salvage, and regenerative therapeutics gather to present cutting-edge advancements. Hemostemix will highlig
Biotechnology, Pharmaceuticals, Health
2025-12-03 2:05 PM EST | Hemostemix Inc.
Microbiome Labs Launches DigestMate, a 2-in-1 Digestive Enzyme and Probiotic Formula
Franklinton, North Carolina--(Newsfile Corp. - December 3, 2025) - Microbiome Labs, a leader in microbiome-based solutions, today announced the launch of DigestMate™, a 2-in-1 digestive enzyme and probiotic formula. Digestive health challenges are on the rise in America, impacting millions of lives and driving demand for innovative solutions. According to recent data from the Centers for Disease Control and Prevention (CDC) and the National Institute of Diabetes and Digestive and
2025-12-03 11:44 AM EST | Microbiome Labs